)
QuidelOrtho (QDEL) investor relations material
QuidelOrtho Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and outlook
Achieved solid Q3 with top-line growth and strong margins, tracking toward full-year targets of mid-single digit base business growth and adjusted EBITDA margin increase from 19.5% to 22% in 2024.
$140 million in cost reductions since mid-2024, mainly from staffing and procurement, driving margin improvements.
Donor screening business shutdown and declining COVID revenue created headwinds, but base business excluding these grew 4–5%.
COVID revenue expected to stabilize at $80 million annually, with no further significant declines anticipated.
China business remains strong, with mid-single digit growth expected to continue through 2026, largely insulated from VBP/DRG impacts due to product mix and technology.
Business segments and growth drivers
Labs business (about half of revenue) expected to maintain mid-single digit growth, supported by new assay approvals.
Immunohematology segment projected to grow 3–4% in 2026, in line with market, with potential for acceleration tied to next-gen platforms.
Triage product experiencing high single-digit growth, especially in China, Latin America, and Europe, aided by expanded sales team.
Point of care segment expected to return to mid-single digit growth in 2026 after timing-related softness in 2024.
Ongoing shift in product mix toward immunoassay, now 30% of analyzer base, contributing 10–20 bps margin uplift annually.
Portfolio optimization and product pipeline
Discontinued Savanna molecular platform in favor of Rheonix, aiming for faster, more cost-effective market entry and menu expansion.
Rheonix launch expected after FDA clearance late 2024 or early 2025, with limited rollout in H1 and broader launch in H2; initial margin dilution expected, turning accretive as volume scales.
No significant margin impact from Savanna discontinuation; one-time charges already absorbed.
Continuous portfolio review and optimization remain a focus, with no new divestitures announced.
Next-gen platform planning underway for Vitros and Labs business; ongoing menu expansion with new assays like High Sensitivity Troponin.
Next QuidelOrtho earnings date
Next QuidelOrtho earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage